Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFEND-1: Otelixizumab in New-Onset Type 1 Diabetes
NCT00678886Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2008
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Otelixizumab with Placebo (2 arms). Primary endpoint: Change From Baseline in 2-hour Mixed Meal Stimulated C-peptide Area Under Curve at 12 months. Started Jul 2008; status: completed.
02
Drugs
otelixizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00678886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00678886.